Press Releases about Acorda Therapeutics
![](https://mms.businesswire.com/media/20240415205418/en/1596352/5/Acorda_Logo-Color_Print.jpg)
Acorda Therapeutics Announces Delisting from Nasdaq
April 15, 2024
From Acorda Therapeutics
Via Business Wire
![](https://mms.businesswire.com/media/20240403709790/en/1596352/5/Acorda_Logo-Color_Print.jpg)
Acorda Therapeutics Announces Nasdaq Delisting Notification
April 03, 2024
From Acorda Therapeutics
Via Business Wire
![](https://mms.businesswire.com/media/20240401939079/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20240401305012/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20240325991670/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20240110989288/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20231113118027/en/1596352/5/Acorda_Logo-Color_Print.jpg)
Acorda Therapeutics Reports Third Quarter 2023 Financial Results
November 13, 2023
From Acorda Therapeutics
Via Business Wire
![](https://mms.businesswire.com/media/20231106959067/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20231106056064/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230808758177/en/1596352/5/Acorda_Logo-Color_Print.jpg)
From Acorda Therapeutics
Via Business Wire
![](https://mms.businesswire.com/media/20230802544540/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230801613678/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230628900808/en/1596352/5/Acorda_Logo-Color_Print.jpg)
From Acorda Therapeutics
Via Business Wire
![](https://mms.businesswire.com/media/20230626647791/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230602005209/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230531005970/en/1596352/5/Acorda_Logo-Color_Print.jpg)
From Acorda Therapeutics
Via Business Wire
![](https://mms.businesswire.com/media/20230530005166/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230511005653/en/1596352/5/Acorda_Logo-Color_Print.jpg)
From Acorda Therapeutics
Via Business Wire
![](https://mms.businesswire.com/media/20230510005117/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230508005309/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230504005726/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230424005261/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230403005358/en/1596352/5/Acorda_Logo-Color_Print.jpg)
From Acorda Therapeutics
Via Business Wire
![](https://mms.businesswire.com/media/20230327005219/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230309005345/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230307005326/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230306005798/en/1596352/5/Acorda_Logo-Color_Print.jpg)
![](https://mms.businesswire.com/media/20230214005861/en/1596352/5/Acorda_Logo-Color_Print.jpg)
Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement
February 14, 2023
From Acorda Therapeutics
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.